EDITORIAL
New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
Zoldonrasib combinations show encouraging response rates in KRAS G12D-mutant pancreatic cancer
Positive findings are reported for first-line zoldonrasib plus chemotherapy and second-line zoldonrasib plus daraxonrasib in two early-phase studies
The place for TACE combinations in hepatocellular carcinoma is still uncertain
Findings from the EMERALD-1 and EMERALD-3 studies suggest that further evidence of benefit is needed and to reflect on the use of surrogate endpoints
Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer
Tumours with no ctDNA-identified pathogenic variants for anti-EGFR drug resistance genes appear to respond to continued cetuximab beyond disease progression
SUPPORTIVE CARE
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
How can regular exercise be integrated into the patient journey?
Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain
TREATMENT OPTIMISATION
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer?
Long-term dostarlimab data suggest that immunotherapy may be used with curative intent in this difficult-to-treat population
Is there a role for intensification immunotherapy in patients with locally advanced cervical cancer?
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
ANTIBODY-DRUG CONJUGATES
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
Sustained quality-of-life benefits reported with first-line antibody-drug conjugate in triple negative breast cancer
Patient-reported outcomes show that datopotamab deruxtecan also improved patient functioning and symptom control compared to chemotherapy
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
OPINIONS
Reshaping the treatment landscape for GI cancers
Elizabeth Smyth
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
Annual PSA screening in men with BRCA2 mutations at high genetic risk of prostate cancer
Heather H. Cheng
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
OPINIONS
Reshaping the treatment landscape for GI cancers
Elizabeth Smyth
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
Annual PSA screening in men with BRCA2 mutations at high genetic risk of prostate cancer
Heather H. Cheng
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic